Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Darnell, Anna
  • Forner, Alejandro|||0000-0002-9014-4950
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Rimola, Jordi|||0000-0002-1814-4198
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Mauro, Ezequiel|||0000-0002-0757-7676
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Ríos, José|||0000-0002-0716-8784
  • Bruix, Jordi|||0000-0002-9826-0753
  • Vilana, Ramon|||0000-0002-2249-1926
  • Reig, María|||0000-0002-5711-9534
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

  • Corominas Argente del Castillo, Josep|||0000-0002-5351-9469
  • Sapena, Victor|||0000-0003-4379-6486
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Millán, Cristina
  • Samper, Esther
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Torres, Ferran|||0000-0002-7355-7913
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Boix, Loreto|||0000-0002-6015-3901
  • Reig, María|||0000-0002-5711-9534
Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyzed the phenotype of 52 sorafenib-treated patients' circulating lymphocytes throughout treatment. We found that different co-stimulatory and immune exhaustion markers, such as Programmed cell death protein 1 (PD-1) and DNAX accessory molecule 1 (DNAM-1) amongst others, correlate with the probability of developing these adverse events, both before and during the treatment. We also compared the phenotype of those lymphocytes expressing DNAM-1 with those that do not, and while NK DNAM-1-expressing cells have a co-stimulatory phenotype, T DNAM-1-expressing cells are immune-suppressors. Overall, we set a rationale for the combination of sorafenib and immune-targeted therapies; and for the use of immune markers (such as DNAM-1) for patients' prognosis evaluation. Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1 + cells express activation markers, T DNAM-1 + cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Sapena, Victor|||0000-0003-4379-6486
  • Boix, Loreto|||0000-0002-6015-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Guedes, Cassia
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darnell, Anna
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Rimola, Jordi|||0000-0002-1814-4198
  • Forner, Alejandro|||0000-0002-9014-4950
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Outcome of liver cancer patients with SARS-CoV-2 infection, An International, Multicentre, Cohort Study

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Ríos, José|||0000-0002-0716-8784
  • Bouattour, Mohamed|||0000-0002-3919-4135
  • El-Kassas, Mohamed|||0000-0002-3396-6894
  • Leal, Cassia R. G.
  • Mocan, Tudor|||0000-0001-7785-6403
  • Nault, Jean-Charles|||0000-0002-4875-9353
  • Alves, Rogerio C. P.
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • García-Juárez, Ignacio|||0000-0003-2400-1887
  • Pinato, David James|||0000-0002-3529-0103
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Alvares-da-Silva, Mario R.|||0000-0002-5001-246X
  • Bandi, Juan C.|||0000-0001-9733-1938
  • Rimassa, Lorenza|||0000-0001-9957-3615
  • Lozano, Mar|||0000-0001-7099-0810
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Tacke, Frank|||0000-0001-6206-0226
  • Sala, Margarita
  • Anders, María|||0000-0002-2238-5322
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Piñero, Federico
  • França, Alex
  • Guarino, Maria|||0000-0002-0460-4122
  • Elvevi, Alessandra
  • Cabibbo, Giuseppe|||0000-0002-0946-3859
  • Peck-Radosavljevic, Markus|||0000-0002-0597-2728
  • Rojas, Ángela|||0000-0003-0853-4800
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Braconi, Chiara|||0000-0003-4835-1259
  • Pascual, Sonia|||0000-0002-4265-5019
  • Perelló, Christie|||0000-0003-0234-2330
  • Mello, Vivianne
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Acevedo, Juan|||0000-0003-4507-2422
  • Villani, Rosanna|||0000-0001-9875-019X
  • Hollande, Clemence|||0000-0002-2287-0635
  • Vilgrain, Valérie
  • Tawheed, Ahmed|||0000-0002-9382-8733
  • Ferguson Theodoro, Carmem|||0000-0001-6605-1060
  • Sparchez, Zeno
  • Blaise, Lorraine
  • Viera-Alves, Daniele E.
  • Watson, Robyn
  • Carrilho, Flair J.
  • Moctezuma-Velázquez, Carlos|||0000-0003-2367-2742
  • D'Alessio, Antonio
  • Iavarone, Massimo|||0000-0003-3493-6504
  • Reig, María|||0000-0002-5711-9534
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p =.0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p =.5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p =.0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication, A Population-Based Cohort Study

  • Ríos, José|||0000-0002-0716-8784
  • Sapena, Victor|||0000-0003-4379-6486
  • Mariño, Zoe|||0000-0001-6321-9534
  • Bruix, Jordi|||0000-0002-9826-0753
  • Forns, Xavier|||0000-0002-8188-1764
  • Morros, Rosa|||0000-0001-6752-8748
  • Reig, María|||0000-0002-5711-9534
  • Torres, Ferran|||0000-0002-7355-7913
  • Pontes García, Caridad|||0000-0002-3274-6048
Background and Objectives: Direct-acting antivirals (DAAs) offer a high rate of hepatitis C virus (HCV) eradication. However, concerns on the risk of cancer after HCV eradication remain. Our study aimed at quantifying the incidence of cancer in patients treated with anti-HCV therapies in Catalonia (Spain) and their matched controls. Methods: This was a population-based study using real-world data from the public healthcare system of Catalonia between 2012 and 2016. Propensity score matching was performed in patients with HCV infection treated with interferon-based therapy (IFN), sequential IFN and DAA (IFN+DAA), and DAA only (DAA) with concurrent controls. We estimated the annual incidence of overall cancer, hepatocellular carcinoma, and non-liver cancer of HCV-treated patients and their corresponding rate ratios. Results: The study included 11,656 HCV-treated patients and 49,545 controls. We found statistically significant increases in the rate of overall cancer for IFN+DAA-treated (rate ratio [RR] 1.77, 95% confidence interval [CI] 1.27-2.46) and DAA-treated patients (RR 1.90, 95% CI 1.66-2.19) and in the rate of HCC for IFN-treated (RR 1.50, 95% CI 1.02-2.22), IFN+DAA-treated (RR 3.89, 95% CI 2.26-6.69), and DAA-treated patients (RR 6.45, 95% CI 4.90-8.49) compared with their corresponding controls. Moreover, DAA-treated patients with cirrhosis showed an increased rate of overall cancer versus those without cirrhosis (RR 1.92, 95% CI 1.51-2.44). Conclusions: Results showed that overall cancer and hepatocellular carcinoma incidence in Catalonia was significantly higher among HCV-treated patients compared with matched non-HCV-infected controls, and risks were higher in patients with cirrhosis. An increased awareness of the potential occurrence of uncommon malignant events and monitoring after HCV eradication therapy may benefit patients.